This phase I/II trial studies the side effects and best dose of nivolumab when given with or without ipilimumab to see how well they work in treating younger patients with solid tumors or sarcomas that have come back (recurrent) or do not respond to treatment (refractory). Monoclonal
The investigators will conduct a phase 1 trial of Selinexor in children with recurrent or refractory solid tumors, including CNS tumors using the Rolling Six design. The aims of the trial will be to establish the maximum tolerated pediatric doses of tablet formulation; to investigate
This phase I trial studies the side effects and best dose of entinostat in treating pediatric patients with solid tumors that have come back or have not responded to treatment. Entinostat may block some of the enzymes needed for cell division and it may help to kill tumor cells.
This is a 2-part study of pembrolizumab (MK-3475) in pediatric participants who have either advanced melanoma or a programmed cell death ligand 1 (PD-L1)-positive advanced, relapsed or refractory solid tumor or lymphoma. Part 1 will find the maximum tolerated dose (MTD)/maximum administered
PURPOSE: The purpose of this study is to test the safety of a study drug
called CPX-351. This drug has been tested in adults but not yet in children and
adolescents. This study tests different doses of the drug to see which dose is
safer in children and adolescents.
Patients who have blood ca
To learn more about available lymphoma clinical trials, contact us at email@example.com or 513-636-2799.
3333 Burnet Avenue, Cincinnati, Ohio 45229-3026
New to Cincinnati Children’s or live outside of the Tristate area? 1-877-881-8479
© 1999-2017 Cincinnati Children's Hospital Medical Center. All rights reserved.